Media stories about Mesoblast (NASDAQ:MESO) have been trending somewhat negative this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Mesoblast earned a media sentiment score of -0.14 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.5980051840574 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

A number of analysts have issued reports on the company. Oppenheimer set a $16.00 price target on Mesoblast and gave the stock a “buy” rating in a report on Wednesday, December 20th. Maxim Group set a $14.00 price target on Mesoblast and gave the stock a “buy” rating in a report on Monday, December 18th. Zacks Investment Research downgraded Mesoblast from a “hold” rating to a “strong sell” rating in a report on Thursday, November 16th. Finally, ValuEngine downgraded Mesoblast from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $13.14.

Mesoblast (MESO) traded down $0.01 during trading on Friday, hitting $5.95. The stock had a trading volume of 39,186 shares, compared to its average volume of 54,833. Mesoblast has a fifty-two week low of $4.80 and a fifty-two week high of $12.50. The stock has a market cap of $509.58, a P/E ratio of -7.63 and a beta of 2.68.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/somewhat-critical-press-coverage-somewhat-unlikely-to-affect-mesoblast-meso-share-price/1798014.html.

Mesoblast Company Profile

Insider Buying and Selling by Quarter for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with Analyst Ratings Network's FREE daily email newsletter.